对于Clostridioides difficile感染的诊断和治疗管理
Miguel Ángel López Zúñiga1, Antonio Sánchez Cabello2, Miguel Ángel López Ruz1
1Unidad de Enfermedades Infecciosas, Hospital Virgen de las Nieves, Granada, España.
概括
困难菌的管理涉及两步诊断方法和fidaxomicin作为症状患者的主要治疗方法. 新兴的治疗方法和预防策略对于高危人群和减少传播至关重要.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 临床实践 临床实践
背景情况:
- 艰难菌感染 (CDI) 在医疗保健环境中构成了重大挑战.
- 有效的诊断和治疗策略对于患者的治疗结果至关重要.
研究的目的:
- 在日常实践中对Clostridioides difficile的诊断和治疗管理算法的全面审查.
- 概述目前和新兴的CDI治疗选择.
主要方法:
- 对Clostridioides difficile.的诊断算法的审查.
- 评估治疗选择,包括菲达克索米辛,万科米辛,美特罗尼达,便微生物群移植和贝兹洛托马布.
- 讨论手术干预和预防措施.
主要成果:
- 建议采用两步诊断算法,包括谷氨酸脱酶免疫检测和毒素PCR.
- 菲达克索米辛是对症状性CDI的首选治疗方法,而不是万科米辛.
- 甲尼达不被认为是充足的治疗方法.
- 便微生物群移植和贝兹洛托克苏马布对于复发和高风险患者很重要.
- 手术只适用于严重并发症的严重病例.
结论:
- 对CDI诊断和治疗的结构化方法可以改善患者管理.
- 菲达克索米辛在最初的CDI治疗中提供了卓越的疗效.
- 新的治疗方法和强有力的预防策略对于控制CDI传播和复发至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
324
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
324
Inflammatory Bowel Disease V: Surgical Management
128
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
128
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Cystic Fibrosis: Management
146
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
146


